Robert Funari Joins Diality’s Board of Directors

Diality Inc. has appointed Robert Funari to its Board of Directors.
 
Funari has spent nearly 50 years in the healthcare industry in public and privately held companies, in both services and medical devices. He has been president and CEO of several companies, including Syncor International (acquired by Cardinal Health) and Crescent Healthcare, and as chairman or director of several companies, including Patient Care America and Beckman Coulter. He was chairman of hemodialysis technology company NxStage Medical until its 2019 acquisition by Fresenius Medical Care. At Baxter International, he held a variety of roles for nearly 20 years, ultimately serving as president of its Pharmaseal division.
 
“Robert has an outstanding, half-century record of bringing his knowledge and strategic thinking to bear on the constantly evolving healthcare market,” Diality CEO Osman Khawar, M.D., said. “His insights will be invaluable as we prepare to bring our new hemodialysis system to market to empower kidney care providers while prioritizing patient care and quality of life.”
 
Diality’s hemodialysis system is designed to be versatile enough for any care setting. Its compact footprint together with an intuitive user interface are intended to enable it to be easily integrated into—and transported within—any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility.
 
“Diality’s novel approach to developing an extremely flexible hemodialysis system interested me from the start,” Funari stated. “I look forward to working with the strong leadership team Osman has assembled to help bring its mission of improving lives impacted by kidney disease to fruition.”
 
Diality also announced that Aaron Mishkin is leaving the board. “We thank Aaron for his dedicated service at Diality, and wish him well in his future endeavors,” Khawar said.
 
Diality is developing a smart hemodialysis platform designed to be as capable and flexible as in-center treatment in an easy-to-use device that’s intended to be safe to operate in any environment. It offers versatility to enable healthcare providers to tailor treatment to each patient’s specific needs. The product is not yet available for use in the European Union or United States and is pending CE Mark and submission and clearance by the U.S. Food and Drug Administration.